Published in J Clin Invest on May 01, 2008
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med (2010) 4.78
Type I interferon: friend or foe? J Exp Med (2010) 4.40
Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 3.73
Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest (2009) 2.96
Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev (2010) 2.55
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev (2008) 1.96
Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med (2009) 1.89
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal (2012) 1.82
Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med (2009) 1.72
Induction of type I interferons by bacteria. Cell Microbiol (2010) 1.70
The role of dendritic cells in autoimmunity. Nat Rev Immunol (2013) 1.68
Interleukin-27: balancing protective and pathological immunity. Immunity (2012) 1.58
Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol (2010) 1.52
Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol (2012) 1.49
Innate immune recognition and activation during HIV infection. Retrovirology (2010) 1.45
Differential effects of IFN-β on IL-12, IL-23, and IL-10 expression in TLR-stimulated dendritic cells. J Leukoc Biol (2015) 1.42
Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012) 1.39
The regulation of inflammation by interferons and their STATs. JAKSTAT (2013) 1.35
Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J Immunol (2010) 1.31
Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev Immunol (2009) 1.29
The Role of TLR2 in Infection and Immunity. Front Immunol (2012) 1.28
Nuanced roles of cytokines in three major human brain disorders. J Clin Invest (2008) 1.28
Th17 cells in autoimmune demyelinating disease. Semin Immunopathol (2010) 1.27
Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 1.26
Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog (2010) 1.26
Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol (2011) 1.24
Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol (2011) 1.24
Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol (2011) 1.18
Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci (2013) 1.17
Inflammasome activation has an important role in the development of spontaneous colitis. Mucosal Immunol (2014) 1.15
More stories on Th17 cells. Cell Res (2009) 1.14
Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One (2011) 1.11
Development, regulation and functional capacities of Th17 cells. Semin Immunopathol (2010) 1.10
Overview of the biology of type I interferons. Arthritis Res Ther (2010) 1.07
Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol (2014) 1.07
Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J Immunol (2013) 1.06
Regulation of TH17 cell differentiation by innate immune signals. Cell Mol Immunol (2012) 1.03
Role of microglia in CNS autoimmunity. Clin Dev Immunol (2013) 1.02
Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice. Gastroenterology (2012) 1.02
Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J (2010) 1.01
Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol (2010) 1.00
IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J Immunol (2010) 0.98
MyD88 and STING signaling pathways are required for IRF3-mediated IFN-β induction in response to Brucella abortus infection. PLoS One (2011) 0.98
IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic airway inflammation. Thorax (2013) 0.97
Current perspectives on the role of IL-17 in autoimmune disease. J Inflamm Res (2010) 0.96
The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes. Immunology (2013) 0.95
Early IL-17 production by intrahepatic T cells is important for adaptive immune responses in viral hepatitis. J Immunol (2012) 0.95
TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B. J Immunol (2011) 0.95
Tolerogenic and activatory plasmacytoid dendritic cells in autoimmunity. Front Immunol (2013) 0.95
Role of toll-like receptors in multiple sclerosis. Am J Clin Exp Immunol (2013) 0.94
A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity. PLoS One (2013) 0.94
dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity. Immunol Rev (2011) 0.93
Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization. J Leukoc Biol (2010) 0.93
Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J Biol Chem (2011) 0.92
Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system. Front Immunol (2012) 0.92
Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by Interferons? Front Immunol (2013) 0.92
Interferon regulatory factor 3 controls interleukin-17 expression in CD8 T lymphocytes. Proc Natl Acad Sci U S A (2013) 0.92
Induction of endogenous Type I interferon within the central nervous system plays a protective role in experimental autoimmune encephalomyelitis. Acta Neuropathol (2015) 0.91
Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO. Cell Mol Immunol (2010) 0.91
Plasmacytoid dendritic cells in HIV infection. Adv Exp Med Biol (2013) 0.90
Depletion of CD4(+)CD25(+) T cells exacerbates experimental autoimmune encephalomyelitis induced by mouse, but not rat, antigens. J Neurosci Res (2009) 0.90
No quiet surrender: molecular guardians in multiple sclerosis brain. J Clin Invest (2015) 0.90
Toll-like receptors in multiple sclerosis. Curr Top Microbiol Immunol (2009) 0.90
Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Hepatology (2014) 0.90
Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis. J Immunol (2013) 0.89
The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunol Rev (2014) 0.89
Multiple Sclerosis and T Lymphocytes: An Entangled Story. J Neuroimmune Pharmacol (2015) 0.89
The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis. Am J Pathol (2009) 0.88
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol (2010) 0.88
MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus. Hum Gene Ther (2010) 0.88
Evidence for a different susceptibility of primate lentiviruses to type I interferons. J Virol (2012) 0.87
Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS. Immunol Cell Biol (2012) 0.87
Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design. Comp Med (2009) 0.87
Lithium controls central nervous system autoimmunity through modulation of IFN-γ signaling. PLoS One (2012) 0.87
Interferon regulatory factor-7 modulates experimental autoimmune encephalomyelitis in mice. J Neuroinflammation (2011) 0.86
Immune heterogeneity in neuroinflammation: dendritic cells in the brain. J Neuroimmune Pharmacol (2012) 0.86
A distinct role of CD4+ Th17- and Th17-stimulated CD8+ CTL in the pathogenesis of type 1 diabetes and experimental autoimmune encephalomyelitis. J Clin Immunol (2011) 0.86
Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol (2008) 0.86
Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev (2012) 0.86
Salmonella Typhimurium Co-Opts the Host Type I IFN System To Restrict Macrophage Innate Immune Transcriptional Responses Selectively. J Immunol (2015) 0.85
The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol (2013) 0.85
Dendritic cells in progression and pathology of HIV infection. Trends Immunol (2013) 0.84
Fueling autoimmunity: type I interferon in autoimmune diseases. Expert Rev Clin Immunol (2013) 0.84
Regulatory effects of IFN-β on the development of experimental autoimmune uveoretinitis in B10RIII mice. PLoS One (2011) 0.84
Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis. J Signal Transduct (2011) 0.84
Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol (2009) 0.84
Localized delivery of interferon-β by Lactobacillus exacerbates experimental colitis. PLoS One (2011) 0.84
IFNγ inhibits Th17 differentiation and function via Tbet-dependent and Tbet-independent mechanisms. J Neuroimmunol (2013) 0.84
Myeloid cells - targets of medication in multiple sclerosis. Nat Rev Neurol (2016) 0.83
Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol Immunol (2016) 0.83
Glatiramer acetate treatment negatively regulates type I interferon signaling. Neurol Neuroimmunol Neuroinflamm (2015) 0.83
Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis. Ann Rheum Dis (2011) 0.83
Trif-dependent induction of Th17 immunity by lung dendritic cells. Mucosal Immunol (2014) 0.83
Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol (2010) 0.82
Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier function. Infect Immun (2014) 0.82
Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. J Biol Chem (2014) 0.81
Interferon regulatory factor (IRF) 3 is critical for the development of experimental autoimmune encephalomyelitis. J Neuroinflammation (2014) 0.81
Modulation of inflammasome-mediated pulmonary immune activation by type I IFNs protects bone marrow homeostasis during systemic responses to Pneumocystis lung infection. J Immunol (2013) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59
IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol (2007) 16.21
IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol (2007) 14.99
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature (2007) 14.28
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity (2007) 12.12
Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53
A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med (2007) 8.97
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med (2006) 7.87
Type I interferons in host defense. Immunity (2006) 7.32
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity (2007) 6.61
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol (2007) 5.99
Toll-like receptor signaling pathways. Science (2003) 5.86
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41
Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol (2007) 4.90
Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol (2006) 4.83
Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol (2007) 4.66
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol (2005) 4.53
Transcriptional regulation of Th17 cell differentiation. Semin Immunol (2007) 3.86
Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet (1987) 3.79
IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med (2007) 3.69
TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol (2005) 2.94
Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol (2007) 2.53
Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection. Proc Natl Acad Sci U S A (1997) 2.46
Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med (2006) 2.46
Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest (2006) 2.17
Autoimmune inflammation from the Th17 perspective. Autoimmun Rev (2006) 2.04
IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol (2007) 1.96
Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol (2006) 1.92
Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J Immunol (2007) 1.87
T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol (2005) 1.86
IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol (2003) 1.68
Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J Exp Med (2007) 1.47
Interferon activation and innate immunity. Rev Immunogenet (2000) 1.31
Interferon-beta: mechanism of action and dosing issues. Neurology (2007) 1.28
IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. J Immunol (2007) 1.26
IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J Neurol Sci (2005) 1.24
Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations. Brain Res (2005) 1.16
Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy (2002) 1.15
Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol (2005) 1.02
Interferon-beta1b in multiple sclerosis. Expert Rev Neurother (2007) 1.02
All in the family: IL-27 suppression of T(H)-17 cells. Nat Immunol (2006) 0.97
T cells doing it for themselves: TGF-beta regulation of Th1 and Th17 cells. Immunity (2007) 0.94
Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol (2007) 0.94
Synergistic interaction between Toll-like receptor agonists is required for induction of experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol (2007) 0.90
Interferons in multiple sclerosis: ten years' experience. Biochimie (2007) 0.84
Multiple sclerosis. Clin Evid (2005) 0.79
Induction of colonic regulatory T cells by indigenous Clostridium species. Science (2010) 16.71
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity (2002) 6.85
Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature (2005) 5.56
Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med (2004) 4.34
MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity (2006) 4.28
LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell (2004) 4.20
Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 4.14
Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol (2008) 3.91
DUBA: a deubiquitinase that regulates type I interferon production. Science (2007) 3.88
IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest (2010) 3.40
Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med (2011) 3.27
Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol (2004) 3.27
Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J (2006) 3.13
DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity (2011) 3.01
Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell (2003) 2.99
Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest (2009) 2.96
Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med (2004) 2.80
The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev (2003) 2.66
Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature (2002) 2.60
Toll-like receptors induce a phagocytic gene program through p38. J Exp Med (2003) 2.49
Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding. Immunity (2012) 2.47
ASC/caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology (2013) 2.45
Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science (2013) 2.34
Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol (2007) 2.32
Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest (2006) 2.29
Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci U S A (2008) 2.22
Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A (2012) 2.18
Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med (2006) 2.17
NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol (2003) 2.15
Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One (2009) 2.14
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
The host type I interferon response to viral and bacterial infections. Cell Res (2005) 2.12
The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol (2012) 2.11
Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation. Sci Signal (2010) 2.05
Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci U S A (2008) 2.05
Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK. J Biol Chem (2007) 1.89
Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J Immunol (2007) 1.87
Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J Immunol (2003) 1.76
Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem (2006) 1.75
New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol (2010) 1.67
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci U S A (2013) 1.60
Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe (2009) 1.55
Neutrophil-derived IL-1β is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PLoS Pathog (2012) 1.52
Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant (2005) 1.51
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity (2013) 1.49
Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol (2004) 1.47
Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A (2004) 1.39
Non-canonical NF-κB signaling activation and regulation: principles and perspectives. Immunol Rev (2011) 1.39
Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell (2010) 1.38
Negative regulation of NF-kappaB signaling by PIAS1. Mol Cell Biol (2005) 1.38
Immune activation of type I IFNs by Listeria monocytogenes occurs independently of TLR4, TLR2, and receptor interacting protein 2 but involves TNFR-associated NF kappa B kinase-binding kinase 1. J Immunol (2005) 1.38
PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res (2008) 1.37
NF-κB and innate immunity. Curr Top Microbiol Immunol (2011) 1.34
Toll-like receptors and innate antiviral responses. Curr Opin Immunol (2003) 1.31
Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J Immunol (2010) 1.31
Conserved herpesviral kinase promotes viral persistence by inhibiting the IRF-3-mediated type I interferon response. Cell Host Microbe (2009) 1.30
TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol (2006) 1.22
Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res (2010) 1.21
From plankton to pathogen recognition. Nat Med (2004) 1.20
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol (2009) 1.18
Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation (2008) 1.17
Structure of the Leanyer orthobunyavirus nucleoprotein-RNA complex reveals unique architecture for RNA encapsidation. Proc Natl Acad Sci U S A (2013) 1.17
Common interaction surfaces of the toll-like receptor 4 cytoplasmic domain stimulate multiple nuclear targets. Mol Cell Biol (2003) 1.16
NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med (2012) 1.14
Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci U S A (2002) 1.13
Downstream regulator TANK binds to the CD40 recognition site on TRAF3. Structure (2002) 1.11
Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One (2011) 1.11
Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology (2011) 1.09
TRAF3 and its biological function. Adv Exp Med Biol (2007) 1.06
Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene (2004) 1.06
TANK-binding kinase-1 plays an important role during in vitro and in vivo type I IFN responses to DNA virus infections. J Immunol (2009) 1.04
PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellular type I interferon signaling pathway. PLoS One (2011) 1.03
A repetitive region of gammaherpesvirus genomic DNA is a ligand for induction of type I interferon. J Virol (2007) 1.02
LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol (2007) 1.01
Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS One (2012) 1.00
The interferon response to bacterial and viral infections. J Endotoxin Res (2006) 1.00
The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death. J Biol Chem (2003) 0.99
NF-kappaB: much learned, much to learn. Sci Signal (2010) 0.96
Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomedicine (2012) 0.96
A role for IRF3-dependent RXRalpha repression in hepatotoxicity associated with viral infections. J Exp Med (2006) 0.96
Single amino acid substitutions confer the antiviral activity of the TRAF3 adaptor protein onto TRAF5. Sci Signal (2012) 0.96
IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody production. J Biol Chem (2007) 0.95
TRAF3: a new regulator of type I interferons. Cell Cycle (2006) 0.92
TLR agonists regulate PDGF-B production and cell proliferation through TGF-beta/type I IFN crosstalk. EMBO J (2005) 0.91
T3JAM, a novel protein that specifically interacts with TRAF3 and promotes the activation of JNK(1). FEBS Lett (2003) 0.88
Structural basis for termination of AIM2-mediated signaling by p202. Cell Res (2013) 0.88
Innate immune system regulation of nuclear hormone receptors in metabolic diseases. J Leukoc Biol (2007) 0.87
Coronavirus MHV-A59 infects the lung and causes severe pneumonia in C57BL/6 mice. Virol Sin (2014) 0.87
Villous B cells of the small intestine are specialized for invariant NK T cell dependence. J Immunol (2008) 0.85
MDA5 is SUMOylated by PIAS2β in the upregulation of type I interferon signaling. Mol Immunol (2010) 0.85
With a little help from my friends: modulation of phagocytosis through TLR activation. Cell Res (2008) 0.84
Crystal structure and nucleotide selectivity of human IFIT5/ISG58. Cell Res (2013) 0.84
A MyD88-dependent IFNγR-CCR2 signaling circuit is required for mobilization of monocytes and host defense against systemic bacterial challenge. Cell Res (2011) 0.82
Macrophage differentiation from embryoid bodies derived from human embryonic stem cells. J Stem Cells (2009) 0.82
Polyinosinic-polycytidylic acid suppresses acetaminophen-induced hepatotoxicity independent of type I interferons and toll-like receptor 3. Hepatology (2011) 0.81
TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through targeting endosomal sorting complex required for transport-I. J Immunol (2011) 0.81
Apoptosis induced by cytoskeletal disruption requires distinct domains of MEKK1. PLoS One (2011) 0.80